Pembrolizumab monotherapy was also evaluated in 12 patients with R/R DLBCL after prior CD19-directed CAR T cell therapy which resulted in 25% ORR (1 CR, 2 PR) (92). This evidence concerns the gene CD19 and diffuse large B-cell lymphoma.